Compare LyondellBasell Industries NV (LYB) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LyondellBasell Industries NV vs Zimmer Biomet Holdings Inc — how do they compare? LyondellBasell Industries NV trades at $63.2 (market cap $20.67B), while Zimmer Biomet Holdings Inc trades at $94.93 (market cap $18.55B). The key difference: LyondellBasell Industries NV and Zimmer Biomet Holdings Inc are close in size by market cap, and LyondellBasell Industries NV pays the higher dividend (6.44%). Which is the better fit depends on your goals.
| LYB | ZBH | |
|---|---|---|
Market Cap | $20.67B | $18.55B |
Sector | Basic Materials | Health |
52-Week High | $82.38 | $107.71 |
52-Week Low | $42.28 | $79.58 |
Enterprise Value | $32.26B | $25.61B |
Dividend Yield | 6.44% | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LyondellBasell Industries (LYB) trades at $62.65, up 5.13% today, reflecting positive momentum following a strong Q2 2026 earnings beat. The stock shows bullish technical signals with moving averages supporting an uptrend, while fundamentals reveal a mixed picture with declining revenue but improving quarterly EPS. Recent news highlights supply disruptions supporting margins and analyst upgrades after the earnings report.
The outlook is cautiously optimistic with a consensus price target of $70.56, suggesting upside potential. Key opportunities include operational leverage from cost cuts and favorable petrochemical supply dynamics, but risks persist from volatile commodity markets and negative net income margins. Institutional sentiment leans positive with recent stake increases.
ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.
The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
